RLM.L Regulatory News (RLM)

Realm Therapeutics plc

("Realm Therapeutics", "Realm" or the "Company")

Realm Therapeutics Appoints Sandy Zweifach as Non-Executive Director & Non-Executive Directors Matthew Hammond and Daniel Hegglin Retire from the Board

17 November 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that Sanford (Sandy) Zweifach has been appointed to the Company's board as a Non-Executive Director effective December 1, 2017.

Mr. Zweifach has over 25 years of experience in the life sciences industry, with an extensive background in corporate partnering, business development, operations, private and public investing, and capital raising. He is Founder, President and Chief Executive Officer (CEO) of Nuvelution Pharma, Inc., a company facilitating the clinical advancement of late stage pharmaceutical and biotechnology assets via a Research and Development risk-sharing approach that deploys capital and human resources. Prior to Nuvelution, Mr. Zweifach held executive leadership roles in the biopharmaceutical industry and life sciences investment banking, including: CEO of Ascendancy Healthcare, Inc.; Managing Director of boutique investment bank Reedland Capital Partners; CEO and President of biomarker development company Pathway Diagnostics Corp.; Chief Financial Officer (CFO) and Managing Director of Bay City Capital, a sector focused venture capital and merchant banking firm; and President and CFO of Epoch Biosciences Corporation which was subsequently acquired by Nanogen.

In addition to serving on the Board of Nuvelution, Mr. Zweifach currently serves as Chairman of IMIDomics, focused on the discovery and application of biomarkers and targets for immune-mediated inflammatory diseases, and Chairman of Lyric Pharmaceuticals (a company developing novel therapeutics to improve the care of critically ill patients). He has served on Audit and Compensation Committees. Mr. Zweifach holds a Masters of Science in Human Physiology from the University of California (UC) Davis and a Bachelor of Arts in Biology from UC San Diego and qualified as a Certified Public Accountant with Coopers & Lybrand.

The Company further announces that current Non-Executive Directors, Matthew Hammond and Daniel Hegglin, will retire from the Board effective today, following the successful completion of the Company's recent financing.

Charles Spicer, Non-Executive Chairman of Realm Therapeutics, commented:

"The Board and I would like to thank Matthew and Danny for their significant contributions to Realm during their tenure, including guiding the transition of the Company to its current drug development focus and the associated divestiture of non-core businesses and repositioning of the business. We wish them both all the best."

Alex Martin, Chief Executive Officer of Realm Therapeutics, added:

"I am excited to welcome Sandy to the Board. His background and experience in both the biopharmaceutical industry and investment banking will be helpful as we progress our pipeline and expand our optionality in 2018 and beyond. I would like to add my thanks to Danny and Matthew for their support and guidance since I joined the Company."

Additional disclosures as required by the AIM Rules for Companies are included at the end of this announcement.

Contact:

Realm Therapeutics plc


Alex Martin, Chief Executive Officer


Marella Thorell, Chief Financial Officer and Chief Operating Officer

+44 (0) 20 3727 1000

FTI Consulting


Simon Conway / Mo Noonan

+44 (0) 20 3727 1000

Argot Partners

Stephanie Marks

+1 212 600 1902

N+1 Singer (Nominated Adviser and Broker) Aubrey Powell / Jen Boorer

+44 (0) 20 7496 3000

About Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programs, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.

Additional disclosures:

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Mr. Sanford Zweifach, aged 61 years, has been a director of the following companies during the five years preceding the date of this announcement.

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.